{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:03:13Z","timestamp":1790298193945,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of the study was to compare the two mucin secretogogues, diquafosol (DQS) and rebamipide (RBM), for the treatment of dry eye syndrome (DES) in office workers. Dry eye patients using computers for &gt;4 h\/day were randomly assigned treatment with either DQS or RBM. Main outcomes measures included changes in tear film break-up time (TBUT) and subjective symptoms assessed by the Dry Eye-Related Quality of Life Score (DEQS). The subjects had scheduled examinations at 0 and 4 weeks, and the examinations at 2 and 8 weeks were optional. Changes in keratoconjunctival fluorescein score and a patient satisfaction questionnaire were also recorded. Both groups showed significant improvements in the DEQS scores at 2, 4, and 8 weeks following the initiation of the study. Both groups showed significant increases in the TBUT at 2 and 4 weeks. No significant difference was found between the DQS and RBM groups at any time periods. Patients reported more comfort with the use of DQS compared with the use of RBM. No local or systemic side effects were noted. The results of the present study indicated that both DQS and RBM were effective for the treatment of DES in office workers.<\/jats:p>","DOI":"10.1038\/s41598-017-13121-9","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T15:07:13Z","timestamp":1509721633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers"],"prefix":"10.1038","volume":"7","author":[{"given":"Jun","family":"Shimazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Den","family":"Seika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,9]]},"reference":[{"key":"13121_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.ophtha.2011.05.029","volume":"118","author":"M Uchino","year":"2011","unstructured":"Uchino, M. et al. Prevalence and risk factors of dry eye disease in Japan: Koumi study. Ophthalmology \n                           118, 2361\u20132367 (2011).","journal-title":"Ophthalmology"},{"key":"13121_CR2","unstructured":"Tsubota, K. et al. New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. Ocul Surf (2016)."},{"key":"13121_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ajo.2013.05.040","volume":"156","author":"M Uchino","year":"2013","unstructured":"Uchino, M. et al. Prevalence of dry eye disease and its risk factors in visual display terminal users: the Osaka study. Am J Ophthalmol \n                           156, 759\u2013766 (2013).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep22480","volume":"6","author":"M Ayaki","year":"2016","unstructured":"Ayaki, M. et al. Sleep and mood disorders in dry eye disease and allied irritating ocular diseases. Sci Rep \n                           6, 22480 (2016).","journal-title":"Sci Rep"},{"key":"13121_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjophthalmol-2013-303953","volume":"98","author":"M Kawashima","year":"2014","unstructured":"Kawashima, M. et al. Decreased tear volume in patients with metabolic syndrome: the Osaka study. Br J Ophthalmol \n                           98, 418\u2013420 (2014).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123299","volume":"10","author":"M Kawashima","year":"2015","unstructured":"Kawashima, M. et al. Associations between subjective happiness and dry eye disease: a new perspective from the Osaka study. PLoS One \n                           10, e0123299 (2015).","journal-title":"PLoS One"},{"key":"13121_CR7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2147\/OPTH.S99620","volume":"10","author":"M Kawashima","year":"2016","unstructured":"Kawashima, M. et al. The association of sleep quality with dry eye disease: the Osaka study. Clin Ophthalmol \n                           10, 1015\u20131021 (2016).","journal-title":"Clin Ophthalmol"},{"key":"13121_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/943786","volume":"2014","author":"M Kawashima","year":"2014","unstructured":"Kawashima, M. et al. The Association between Dry Eye Disease and Physical Activity as well as Sedentary Behavior: Results from the Osaka Study. J Ophthalmol \n                           2014, 943786 (2014).","journal-title":"J Ophthalmol"},{"key":"13121_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1136\/bjophthalmol-2013-303838","volume":"97","author":"A Labbe","year":"2013","unstructured":"Labbe, A. et al. Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study. Br J Ophthalmol \n                           97, 1399\u20131403 (2013).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/02713683.2010.519850","volume":"36","author":"M Li","year":"2011","unstructured":"Li, M., Gong, L., Sun, X. & Chapin, W. J. Anxiety and depression in patients with dry eye syndrome. Curr Eye Res \n                           36, 1\u20137 (2011).","journal-title":"Curr Eye Res"},{"key":"13121_CR11","unstructured":"Szakats, I., Sebestyen, M., Nemeth, J., Birkas, E. & Purebl, G. The Role of Health Anxiety and Depressive Symptoms in Dry Eye Disease. Curr Eye Res, 1\u20136 (2015)."},{"key":"13121_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ajo.2013.10.014","volume":"157","author":"M Uchino","year":"2014","unstructured":"Uchino, M. et al. Dry eye disease and work productivity loss in visual display users: the Osaka study. Am J Ophthalmol \n                           157, 294\u2013300 (2014).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR13","doi-asserted-by":"crossref","unstructured":"Wan, K. H., Chen, L. J. & Young, A. L. Depression and anxiety in dry eye disease: a systematic review and meta-analysis. Eye (Lond) (2016).","DOI":"10.1038\/eye.2016.186"},{"key":"13121_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson, D., Tauber, J. & Reis, B. L. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology \n                           107, 967\u2013974 (2000).","journal-title":"Ophthalmology"},{"key":"13121_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/sj.eye.6700169","volume":"16","author":"CC McDonald","year":"2002","unstructured":"McDonald, C. C., Kaye, S. B., Figueiredo, F. C., Macintosh, G. & Lockett, C. A. randomised, crossover, multicentre study to compare the performance of 0.1% (w\/v) sodium hyaluronate with 1.4% (w\/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) \n                           16, 601\u2013607 (2002).","journal-title":"Eye (Lond)"},{"key":"13121_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/bjo.79.11.1007","volume":"79","author":"S Shimmura","year":"1995","unstructured":"Shimmura, S. et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol \n                           79, 1007\u20131011 (1995).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR17","first-page":"929","volume":"20","author":"T Kojima","year":"2014","unstructured":"Kojima, T. et al. The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice. Mol Vis \n                           20, 929\u2013938 (2014).","journal-title":"Mol Vis"},{"key":"13121_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/02713683.2016.1233986","volume":"42","author":"KE Choi","year":"2017","unstructured":"Choi, K. E., Song, J. S., Kang, B., Eom, Y. & Kim, H. M. Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. Curr Eye Res \n                           42, 666\u2013671 (2017).","journal-title":"Curr Eye Res"},{"key":"13121_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/10807680260218524","volume":"18","author":"T Fujihara","year":"2002","unstructured":"Fujihara, T., Murakami, T., Nagano, T., Nakamura, M. & Nakata, K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther \n                           18, 363\u2013370 (2002).","journal-title":"J Ocul Pharmacol Ther"},{"key":"13121_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3109\/02713683.2014.967871","volume":"40","author":"C Shigeyasu","year":"2015","unstructured":"Shigeyasu, C., Hirano, S., Akune, Y. & Yamada, M. Diquafosol Tetrasodium Increases the Concentration of Mucin-like Substances in Tears of Healthy Human Subjects. Curr Eye Res \n                           40, 878\u2013883 (2015).","journal-title":"Curr Eye Res"},{"key":"13121_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/jop.2011.0142","volume":"28","author":"Y Takeji","year":"2012","unstructured":"Takeji, Y., Urashima, H., Aoki, A. & Shinohara, H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther \n                           28, 259\u2013263 (2012).","journal-title":"J Ocul Pharmacol Ther"},{"key":"13121_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","volume":"23","author":"H Urashima","year":"2004","unstructured":"Urashima, H., Okamoto, T., Takeji, Y., Shinohara, H. & Fujisawa, S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea \n                           23, 613\u2013619 (2004).","journal-title":"Cornea"},{"key":"13121_CR23","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1167\/iovs.13-13128","volume":"54","author":"T Ohguchi","year":"2013","unstructured":"Ohguchi, T. et al. The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice. Invest Ophthalmol Vis Sci \n                           54, 7793\u20137802 (2013).","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"13121_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jamaophthalmol.2014.431","volume":"132","author":"S Kase","year":"2014","unstructured":"Kase, S., Shinohara, T. & Kase, M. Effect of topical rebamipide on human conjunctival goblet cells. JAMA Ophthalmol \n                           132, 1021\u20131022 (2014).","journal-title":"JAMA Ophthalmol"},{"key":"13121_CR25","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3892\/etm.2017.4390","volume":"13","author":"S Kase","year":"2017","unstructured":"Kase, S., Shinohara, T., Kase, M. & Ishida, S. Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva. Exp Ther Med \n                           13, 3516\u20133522 (2017).","journal-title":"Exp Ther Med"},{"key":"13121_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exer.2016.10.007","volume":"153","author":"Y Uchino","year":"2016","unstructured":"Uchino, Y., Woodward, A. M. & Argueso, P. Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells. Exp Eye Res \n                           153, 1\u20137 (2016).","journal-title":"Exp Eye Res"},{"key":"13121_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1136\/bjophthalmol-2014-305425","volume":"98","author":"K Fukuda","year":"2014","unstructured":"Fukuda, K., Ishida, W., Tanaka, H., Harada, Y. & Fukushima, A. Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts. Br J Ophthalmol \n                           98, 1751\u20131755 (2014).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/bjophthalmol-2012-302868","volume":"97","author":"H Tanaka","year":"2013","unstructured":"Tanaka, H. et al. Rebamipide increases barrier function and attenuates TNFalpha-induced barrier disruption and cytokine expression in human corneal epithelial cells. Br J Ophthalmol \n                           97, 912\u2013916 (2013).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR29","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1089\/jop.2012.0054","volume":"29","author":"M Ueta","year":"2013","unstructured":"Ueta, M., Sotozono, C., Yokoi, N. & Kinoshita, S. Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. J Ocul Pharmacol Ther \n                           29, 688\u2013693 (2013).","journal-title":"J Ocul Pharmacol Ther"},{"key":"13121_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","volume":"99","author":"L Gong","year":"2015","unstructured":"Gong, L. et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol \n                           99, 903\u2013908 (2015).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1272\/jnms.82.229","volume":"82","author":"T Igarashi","year":"2015","unstructured":"Igarashi, T. et al. Improvements in Signs and Symptoms of Dry Eye after Instillation of 2% Rebamipide. J Nippon Med Sch \n                           82, 229\u2013236 (2015).","journal-title":"J Nippon Med Sch"},{"key":"13121_CR32","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","volume":"119","author":"S Kinoshita","year":"2012","unstructured":"Kinoshita, S. et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology \n                           119, 2471\u20132478 (2012).","journal-title":"Ophthalmology"},{"key":"13121_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","volume":"120","author":"S Kinoshita","year":"2013","unstructured":"Kinoshita, S. et al. A Randomized, Multicenter Phase 3 Study Comparing 2% Rebamipide (OPC-12759) with 0.1% Sodium Hyaluronate in the Treatment of Dry Eye. Ophthalmology \n                           120, 1158\u20131165 (2013).","journal-title":"Ophthalmology"},{"key":"13121_CR34","volume":"2016","author":"JH Lee","year":"2016","unstructured":"Lee, J. H., Song, I. S., Kim, K. L. & Yoon, S. Y. Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery. J Ophthalmol \n                           2016, 8150757 (2016).","journal-title":"J Ophthalmol"},{"key":"13121_CR35","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto, Y., Ohashi, Y., Watanabe, H. & Tsubota, K. & Diquafosol Ophthalmic Solution Phase 2 Study, G. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology \n                           119, 1954\u20131960 (2012).","journal-title":"Ophthalmology"},{"key":"13121_CR36","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/ICO.0b013e3182930b1d","volume":"32","author":"S Shimazaki-Den","year":"2013","unstructured":"Shimazaki-Den, S., Iseda, H., Dogru, M. & Shimazaki, J. Effects of diquafosol sodium eye drops on tear film stability in short but type of dry eye. Cornea \n                           32, 1120\u20131125 (2013).","journal-title":"Cornea"},{"key":"13121_CR37","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura, E., Tsubota, K., Watanabe, H., Ohashi, Y. & Group, D. O. S. P. S. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol \n                           96, 1310\u20131315 (2012).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR38","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","volume":"23","author":"J Tauber","year":"2004","unstructured":"Tauber, J. et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea \n                           23, 784\u2013792 (2004).","journal-title":"Cornea"},{"key":"13121_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/ICO.0000000000000429","volume":"34","author":"D Wu","year":"2015","unstructured":"Wu, D., Chen, W. Q., Li, R. & Wang, Y. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials. Cornea \n                           34, 644\u2013650 (2015).","journal-title":"Cornea"},{"key":"13121_CR40","first-page":"2251","volume":"9","author":"M Yamaguchi","year":"2015","unstructured":"Yamaguchi, M. et al. Real-world assessment of diquafosol in dry eye patients with risk factors such as contact lens, meibomian gland dysfunction, and conjunctivochalasis: subgroup analysis from a prospective observational study. Clin Ophthalmol \n                           9, 2251\u20132256 (2015).","journal-title":"Clin Ophthalmol"},{"key":"13121_CR41","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/eye.2015.125","volume":"29","author":"N Yokoi","year":"2015","unstructured":"Yokoi, N., Sonomura, Y., Kato, H., Komuro, A. & Kinoshita, S. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjogren\u2019s syndrome. Eye (Lond) \n                           29, 1204\u20131212 (2015).","journal-title":"Eye (Lond)"},{"key":"13121_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","volume":"143","author":"B Miljanovic","year":"2007","unstructured":"Miljanovic, B., Dana, R., Sullivan, D. A. & Schaumberg, D. A. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol \n                           143, 409\u2013415 (2007).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR43","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ajo.2014.12.019","volume":"159","author":"N Yokoi","year":"2015","unstructured":"Yokoi, N. et al. Importance of tear film instability in dry eye disease in office workers using visual display terminals: the Osaka study. Am J Ophthalmol \n                           159, 748\u2013754 (2015).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1001\/jamaophthalmol.2014.1008","volume":"132","author":"Y Uchino","year":"2014","unstructured":"Uchino, Y. et al. Alteration of tear mucin 5AC in office workers using visual display terminals: The Osaka Study. JAMA Ophthalmol \n                           132, 985\u2013992 (2014).","journal-title":"JAMA Ophthalmol"},{"key":"13121_CR45","doi-asserted-by":"crossref","unstructured":"Baek, J., Doh, S.H. & Chung, S.K. The Effect of Topical Diquafosol Tetrasodium 3% on Dry Eye After Cataract Surgery. Curr Eye Res, 1\u20135 (2016).","DOI":"10.3109\/02713683.2015.1122813"},{"key":"13121_CR46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1089\/jop.2012.0246","volume":"29","author":"M Kaido","year":"2013","unstructured":"Kaido, M., Uchino, M., Kojima, T., Dogru, M. & Tsubota, K. Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye. J Ocul Pharmacol Ther \n                           29, 595\u2013603 (2013).","journal-title":"J Ocul Pharmacol Ther"},{"key":"13121_CR47","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","volume":"32","author":"S Koh","year":"2013","unstructured":"Koh, S., Inoue, Y., Sugmimoto, T., Maeda, N. & Nishida, K. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea \n                           32, 1219\u20131223 (2013).","journal-title":"Cornea"},{"key":"13121_CR48","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ajo.2013.11.017","volume":"157","author":"I Toda","year":"2014","unstructured":"Toda, I. et al. Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis. Am J Ophthalmol \n                           157, 616\u2013622 e611 (2014).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR49","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s12325-014-0162-4","volume":"31","author":"M Yamaguchi","year":"2014","unstructured":"Yamaguchi, M. et al. Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study. Adv Ther \n                           31, 1169\u20131181 (2014).","journal-title":"Adv Ther"},{"key":"13121_CR50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2013.09.009","volume":"157","author":"N Yokoi","year":"2014","unstructured":"Yokoi, N., Kato, H. & Kinoshita, S. Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes. Am J Ophthalmol \n                           157, 85\u201392 e81 (2014).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR51","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/bjophthalmol-2012-302668","volume":"97","author":"R Arita","year":"2013","unstructured":"Arita, R. et al. Topical diquafosol for patients with obstructive meibomian gland dysfunction. Br J Ophthalmol \n                           97, 725\u2013729 (2013).","journal-title":"Br J Ophthalmol"},{"key":"13121_CR52","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S54511","volume":"7","author":"H Itakura","year":"2013","unstructured":"Itakura, H., Kashima, T., Itakura, M., Akiyama, H. & Kishi, S. Topical rebamipide improves lid wiper epitheliopathy. Clin Ophthalmol \n                           7, 2137\u20132141 (2013).","journal-title":"Clin Ophthalmol"},{"key":"13121_CR53","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ajo.2013.12.027","volume":"157","author":"Y Takahashi","year":"2014","unstructured":"Takahashi, Y., Ichinose, A. & Kakizaki, H. Topical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye disease. Am J Ophthalmol \n                           157, 807\u2013812 e802 (2014).","journal-title":"Am J Ophthalmol"},{"key":"13121_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2332\/allergolint.13-OA-0605","volume":"63","author":"M Ueta","year":"2014","unstructured":"Ueta, M., Sotozono, C., Koga, A., Yokoi, N. & Kinoshita, S. Usefulness of a new therapy using rebamipide eyedrops in patients with VKC\/AKC refractory to conventional anti-allergic treatments. Allergol Int \n                           63, 75\u201381 (2014).","journal-title":"Allergol Int"},{"key":"13121_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/02713683.2013.834939","volume":"39","author":"S Itoh","year":"2014","unstructured":"Itoh, S., Itoh, K. & Shinohara, H. Regulation of human corneal epithelial mucins by rebamipide. Curr Eye Res \n                           39, 133\u2013141 (2014).","journal-title":"Curr Eye Res"},{"key":"13121_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/OPX.0000000000000877","volume":"93","author":"C Shigeyasu","year":"2016","unstructured":"Shigeyasu, C., Yamada, M., Akune, Y. & Fukui, M. Diquafosol for Soft Contact Lens Dryness: Clinical Evaluation and Tear Analysis. Optom Vis Sci \n                           93, 973\u2013978 (2016).","journal-title":"Optom Vis Sci"},{"key":"13121_CR57","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.opx.0000232814.39651.fa","volume":"83","author":"M Uchino","year":"2006","unstructured":"Uchino, M. et al. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci \n                           83, 797\u2013802 (2006).","journal-title":"Optom Vis Sci"},{"key":"13121_CR58","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","volume":"131","author":"Y Sakane","year":"2013","unstructured":"Sakane, Y. et al. Development and validation of the Dry Eye-Related Quality-of-Life Score questionnaire. JAMA Ophthalmol \n                           131, 1331\u20131338 (2013).","journal-title":"JAMA Ophthalmol"},{"key":"13121_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/archopht.1969.00990020012003","volume":"82","author":"OP van Bijsterveld","year":"1969","unstructured":"van Bijsterveld, O. P. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol \n                           82, 10\u201314 (1969).","journal-title":"Arch Ophthalmol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13121-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13121-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13121-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:17:40Z","timestamp":1671801460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13121-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["13121"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-13121-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]},"assertion":[{"value":"3 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by a grant from Santen Pharmaceutical Company. Personal financial interests: J.S. and D.S. received financial supports from Santen Pharmaceutical Company and Otsuka Pharmaceutical Company for reimbursement for attending symposia. J.S. also received financial supports from Santen Pharmaceutical Company and Otsuka Pharmaceutical Company for his scientific advisory board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15210"}}